Product Name :
AS1810722
Description:
AS1810722 is an orally active and potent STAT6 inhibitor with an IC50 of 1.9 nM. AS1810722 shows a good profile of CYP3A4 inhibition. AS1810722, a derivative of fused bicyclic pyrimidine, has the potential for allergic diseases such as asthma and atopic diseases research.
CAS:
909561-15-5
Molecular Weight:
477.51
Formula:
C25H25F2N7O
Chemical Name:
2-{4-[4-({7-[(3, 5-difluorophenyl)methyl]-7H-pyrrolo[2, 3-d]pyrimidin-2-yl}amino)phenyl]piperazin-1-yl}acetamide
Smiles :
NC(=O)CN1CCN(CC1)C1C=CC(=CC=1)NC1=NC2=C(C=N1)C=CN2CC1C=C(F)C=C(F)C=1
InChiKey:
IJFRMEXSGYTWGY-UHFFFAOYSA-N
InChi :
InChI=1S/C25H25F2N7O/c26-19-11-17(12-20(27)13-19)15-34-6-5-18-14-29-25(31-24(18)34)30-21-1-3-22(4-2-21)33-9-7-32(8-10-33)16-23(28)35/h1-6,11-14H,7-10,15-16H2,(H2,28,35)(H,29,30,31)
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥360 days if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.{{Ribavirin} site|{Ribavirin} Anti-infection|{Ribavirin} Purity & Documentation|{Ribavirin} Description|{Ribavirin} custom synthesis|{Ribavirin} Cancer}
Additional information:
AS1810722 is an orally active and potent STAT6 inhibitor with an IC50 of 1.{{Dehydroabietic acid} medchemexpress|{Dehydroabietic acid} PPAR|{Dehydroabietic acid} Technical Information|{Dehydroabietic acid} Description|{Dehydroabietic acid} manufacturer|{Dehydroabietic acid} Epigenetics} 9 nM. AS1810722 shows a good profile of CYP3A4 inhibition. AS1810722, a derivative of fused bicyclic pyrimidine, has the potential for allergic diseases such as asthma and atopic diseases research.|Product information|CAS Number: 909561-15-5|Molecular Weight: 477.51|Formula: C25H25F2N7O|Chemical Name: 2-{4-[4-({7-[(3, 5-difluorophenyl)methyl]-7H-pyrrolo[2, 3-d]pyrimidin-2-yl}amino)phenyl]piperazin-1-yl}acetamide|Smiles: NC(=O)CN1CCN(CC1)C1C=CC(=CC=1)NC1=NC2=C(C=N1)C=CN2CC1C=C(F)C=C(F)C=1|InChiKey: IJFRMEXSGYTWGY-UHFFFAOYSA-N|InChi: InChI=1S/C25H25F2N7O/c26-19-11-17(12-20(27)13-19)15-34-6-5-18-14-29-25(31-24(18)34)30-21-1-3-22(4-2-21)33-9-7-32(8-10-33)16-23(28)35/h1-6,11-14H,7-10,15-16H2,(H2,28,35)(H,29,30,31)|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 62.5 mg/mL (130.89 mM; Need ultrasonic)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.PMID:33301803 |Shelf Life: ≥360 days if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|AS1810722 (compound 24) inhibits production of IL-4 with an IC50 of 2.4 nM, but shows no effect on production of IFN-γ.|In Vivo:|AS1810722 (compound 24; 0.03-0.3 mg/kg; orally; 30 min before, and 24h and 48 h after OVA exposure) suppress eosinophil infiltration in the lung in a dose-dependent manner in an antigen-induced mouse asthmatic model. AS1810722 inhibits in vitro Th2 differentiation with an IC50 of 2.4 nM without affecting type 1 helper T (Th1) cell differentiation and eosinophil infiltration in an antigen-induced mouse asthmatic model after oral administration.|References:|Shinya Nagashima, et al. Novel 7H-pyrrolo[2,3-d]pyrimidine derivatives as potent and orally active STAT6 inhibitors. Bioorg Med Chem. 2009 Oct 1;17(19):6926-36.Products are for research use only. Not for human use.|
